Keeping it tight down the stretch
I think his agenda is pretty simple..... get it on the market..... show penetration.... sell at a premium.
Its just going to take more time.
My wife is Type I. She is excited to try afrezza for a couple of real word applications. I am sure she is not alone with these needs.
1) She often battles early morning highs and loves the concept of using afrezza to quickly battle this glucose spike.
2) She uses an insulin pump and when on vacation she hates to wear it at the beach due to its appearance. Given afrezza's ease of use and relative temperature stability she will use it when we are on vacation + Lantus pen.
3) She tried Exubera but didn't like it because of the cumbersome and embarrassing bong.
I know that, but it makes me feel better.
Of course you are stating the legal requirements for handling cash accounts.
What are the illegal tactics for handling cash accounts?
What the heck I put in my limit sell order for 42.00 a share.
Strange thing is my online account repeatedly said symbol not found when I tried to do it. I have never seen this before.
I agree seyhey and I am in for 50 pps. I believe however that you are underestimating the potential for afrezza in the type II market as an add on for post meal control. Just as an example here is an snippit from Novo:
(Reuters) - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza maintained superior blood sugar reduction after one year than either medicine separately, according to data from a late stage trial presented on Saturday.
After 52 weeks of treatment, patients taking the combination drug IDegLira had an average 1.8 percent reduction in A1c levels - a common measure of blood sugar over time. That compared with an average A1c decline of 1.4 percent for the insulin and 1.2 percent for Victoza, known chemically as liraglutide.
Combination therapies for the growing type 2 diabetes health crisis are becoming increasingly common as patients continually require additional medicines as the disease progresses. As many as a third of all Americans could have diabetes by 2050 if present trends continue unabated, the ADA has cautioned.
Our type II Phase III study was in COMBINATION with metformin, the most commonly prescribed medication for type II. IMHO the real value of Afrezza isn't to capture metformins market or victoza or trajenta but as an add on to all of these treatments to privide a surgical dose of insulin after meals. Best of luck to all longs and I can't wait to hear how Sanofi is planning to market this.
I may be wrong but I thought SNY bought afrezza from mnkd at cost? Either way the 35% is straight profit.
I hear you Kevin and believe me I feel your frustrations.
The question I keep asking myself is this: Did SNY invest 150M upfront advance 175M for production 750M in milestone payments ensure mnkd debt be made whole before profit sharing because they thought afrezza was only going to sell 1B a year?
That equates approx to .65% X 500M or 325M a year? I say approx because we have no idea what profit margin is so assume 50%.
I never claim to know everything but I do respect the opinions of those who demonstrate deep knowledge in their area of expertise. SNY believes in afrezza and I respect their opinion.
Thank you sir. Where exactly is that info in the report? Seems low? Operating margin would take all expenses into account? Facilities, manufacture, possibly R&D figured in as well? Those are operational expenses not just sales and marketing. Thanks for the info!
Why is this so hard to find? This information would be great to know in light of the profit sharing agreement with SNY. Anybody??
Potential cost reductions with biosimilars are estimated at 18-50%.13 14 15 Profit margins are smaller than for conventional drugs, leaving less room for discounting. One report estimates that etanercept for rheumatoid arthritis has a gross margin of about 67%, compared with over 90% for a typical small molecule drug.16
AKA what are the earnings vs revenue for these products? I have been trying to find this information but cannot seem to get a good handle on it.
If anyone has a good source for this information I would greatly appreciate it.